{"id":510961,"date":"2018-08-20T11:31:17","date_gmt":"2018-08-20T15:31:17","guid":{"rendered":"https:\/\/www.sciencedaily.com\/releases\/2018\/08\/180820113117.htm"},"modified":"2018-08-20T11:31:17","modified_gmt":"2018-08-20T15:31:17","slug":"stat3-can-be-a-therapeutic-target-for-chronic-active-ebv-infection-a-fatal-disorder","status":"publish","type":"post","link":"https:\/\/spaceweekly.com\/?p=510961","title":{"rendered":"STAT3 can be a therapeutic target for chronic active EBV infection, a fatal disorder"},"content":{"rendered":"<p>Chronic active Epstein-Barr virus infection (CAEBV) is an inflammatory disorder with potential for tumor development. Here, unusual phosphorylation was observed on STAT3 in EBV-infected T- or NK-cells from patients with CAEBV. Researchers found that ruxolitinib, a drug that is currently used for treatment of myelofibrosis and polycythemia vera, could suppress the survival of these EBV-infected cells in a dose-dependent manner, and that STAT3 could be an important new target for treatment of CAEBV. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chronic active Epstein-Barr virus infection (CAEBV) is an inflammatory disorder with potential for tumor development. Here, unusual phosphorylation was observed on STAT3 in EBV-infected T- or NK-cells from patients with CAEBV. Researchers found that ru&#8230;<\/p>\n","protected":false},"author":61,"featured_media":615444,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/510961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/users\/61"}],"replies":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=510961"}],"version-history":[{"count":1,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/510961\/revisions"}],"predecessor-version":[{"id":510962,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/posts\/510961\/revisions\/510962"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=\/wp\/v2\/media\/615444"}],"wp:attachment":[{"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=510961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=510961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/spaceweekly.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=510961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}